Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

Ezh2 represses effector genes that contribute to the development of tumor-mediated CD8+ T-cell exhaustion

5 affiliations
  1. 1Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
  2. 21University of Pittsburgh, Pittsburgh, USA
  3. 3University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  4. 4Department of Pediatrics, Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
  5. 5Center for Systems Immunology, Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Abstract

Background CD8+ T cells differentiate into terminally exhausted T cells, a hypofunctional state induced in tumor environments that leads to impaired antitumor immunity and poor cancer prognosis. Therapeutic approaches to improve effector CD8+ T-cell function by limiting or reversing tumor-mediated exhaustion are areas of active investigation. Terminally exhausted CD8+ T cells from tumors exhibit increased transcriptional repression of effector genes by tri-methylation of histone 3 lysine 27 (H3K27me3). Enhancer of zeste homolog 2 (Ezh2) is a crucial enzyme acting as the catalytic core of the polycomb repressive complex 2, which adds H3K27me3 in T cells.Methods Using pharmacologic and genetic suppression of Ezh2, we evaluated its role in driving CD8+ T-cell exhaustion in vitro and in murine melanoma models in vivo, including its impact on functional restoration.Results Ezh2 expression is significantly increased in CD8+ T cells exposed to chronic stimulation. Suppression of Ezh2 significantly increased the proportion of CD8+ T cells expressing both tumor necrosis factor and interferon-γ when exposed to chronic stimulation in vitro or in the tumor. Ezh2-deficient CD8+ T cells also exhibited decreases in the exhaustion-mediated transcription factor Tox. Multiple genes were upregulated when Ezh2 was deleted, including cytokines related to type 1 (eg, Gzmc) and type 2 (eg, Il13) immunity, and treatment with interleukin (IL)-4 induced a significantly higher proportion of IL-13-expressing CD8+ T cells.Conclusions These findings suggest that Ezh2 contributes to epigenetic modifications supporting T-cell exhaustion, and Ezh2 suppression or deletion can rescue effector functions of exhausted CD8+ T cells. Thus, Ezh2 may be a therapeutic target to improve antitumor immunity.

Related

  1. 772 TOX maintains T cell exhaustion and hinders the development of tumor-specific CD8+ T cell memory
    Creg Workman, Erin Brunazzi, Dario AA Vignali +1
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textImmunologyDOAJ
  2. Interaction with complement factor C1q can contribute to and improve monoclonal antibody-mediated protection against lethal HSV-1 challenge
    Lesle M. Jimenez, Matthew D. Slein, David A. Leib +1
    bioRxivPreprintCC BY-NCFull textImmunologybioRxivPMC
  3. Angiopoietin-like protein 7 (ANGPTL7)-mediated effects on resident immune cells contribute to neurodegeneration in glaucomatous optic nerve head
    T. R. Vollmer, K. Dolan, C. Xiang +27
    bioRxivPreprintCC BY-NC-NDFull textNeurosciencebioRxiv
  4. A self-limiting dimeric TIR effector specialised for type III CRISPR-mediated immunity
    Y. Sun, S. McMahon, S. Snyowsky +1
    bioRxivPreprintCC BYFull textMicrobiologybioRxiv
  5. Sph-mediated mtDNA release and autophagy-dependent ferroptosis contribute to Staphylococcus aureus-induced mastitis
    Yunfei Wei, Xinyu Zhao, Ziyi Yin +9
    PLOS PathogensPeer-reviewedCC BY 4.0Full textCell biologyGenetics & genomicsPLOS
BibTeX
@article{delgoffe2026ezh2,
  title = {{Ezh2 represses effector genes that contribute to the development of tumor-mediated CD8+ T-cell exhaustion}},
  author = {Greg M Delgoffe and Hannah Bumgarner and Catherine Yang and Aaron Yang and Amanda C Poholek and Xingjian Qiu and B Rhodes Ford and Shilpi Giri},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-016004},
  url = {https://doi.org/10.1136/jitc-2026-016004},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Ezh2 represses effector genes that contribute to the development of tumor-mediated CD8+ T-cell exhaustion
AU  - Greg M Delgoffe
AU  - Hannah Bumgarner
AU  - Catherine Yang
AU  - Aaron Yang
AU  - Amanda C Poholek
AU  - Xingjian Qiu
AU  - B Rhodes Ford
AU  - Shilpi Giri
PY  - 2026
DA  - 2026/11/16
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-016004
UR  - https://doi.org/10.1136/jitc-2026-016004
AB  - Background CD8+ T cells differentiate into terminally exhausted T cells, a hypofunctional state induced in tumor environments that leads to impaired antitumor immunity and poor cancer prognosis. Therapeutic approaches to improve effector CD8+ T-cell function by limiting or reversing tumor-mediated exhaustion are areas of active investigation. Terminally exhausted CD8+ T cells from tumors exhibit increased transcriptional repression of effector genes by tri-methylation of histone 3 lysine 27 (H3K27me3). Enhancer of zeste homolog 2 (Ezh2) is a crucial enzyme acting as the catalytic core of the polycomb repressive complex 2, which adds H3K27me3 in T cells.Methods Using pharmacologic and genetic suppression of Ezh2, we evaluated its role in driving CD8+ T-cell exhaustion in vitro and in murine melanoma models in vivo, including its impact on functional restoration.Results Ezh2 expression is significantly increased in CD8+ T cells exposed to chronic stimulation. Suppression of Ezh2 significantly increased the proportion of CD8+ T cells expressing both tumor necrosis factor and interferon-γ when exposed to chronic stimulation in vitro or in the tumor. Ezh2-deficient CD8+ T cells also exhibited decreases in the exhaustion-mediated transcription factor Tox. Multiple genes were upregulated when Ezh2 was deleted, including cytokines related to type 1 (eg, Gzmc) and type 2 (eg, Il13) immunity, and treatment with interleukin (IL)-4 induced a significantly higher proportion of IL-13-expressing CD8+ T cells.Conclusions These findings suggest that Ezh2 contributes to epigenetic modifications supporting T-cell exhaustion, and Ezh2 suppression or deletion can rescue effector functions of exhausted CD8+ T cells. Thus, Ezh2 may be a therapeutic target to improve antitumor immunity.
SN  - 2051-1426
ER  -